SCHEMBL7925344

SCHEMBL7925344

CC(=O)c1ccccc1Nc1cccc(C)c1C

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.76
AKR1C3 P42330 4/20 0.76
LMNA P02545 3/20 0.76
AKR1C2 P52895 3/20 0.76
MEN1 O00255 2/20 0.76
CYP1A2 P05177 2/20 0.76
CYP3A4 P08684 2/20 0.76
CYP2C9 P11712 2/20 0.76
KMT2A Q03164 2/20 0.76
HIF1A Q16665 2/20 0.76
PTGS1 P23219 2/20 0.76
AKR1B10 O60218 2/20 0.76
AKR1B1 P15121 2/20 0.76
AKR1C1 Q04828 2/20 0.76
TRPA1 O75762 1/20 0.76
ABCB11 O95342 1/20 0.76
DHFR P00374 1/20 0.76
MPO P05164 1/20 0.76
CHRM1 P11229 1/20 0.76
NAPRT Q6XQN6 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5321483 0.87 AKR1C3 (0.57) PTGS2AKR1C3LMNAAKR1C2MEN1
Mefenamic Acid SCHEMBL29355128 0.86 PTGS2 (1.00) PTGS2AKR1C3LMNAAKR1C2MEN1
Mefenamic Acid SCHEMBL6421234 0.86 PTGS2 (1.00) PTGS2AKR1C3LMNAAKR1C2MEN1
Mefenamic Acid SCHEMBL3544 0.86 PTGS2 (1.00) PTGS2AKR1C3LMNAAKR1C2MEN1
Mefenamic Acid SCHEMBL29350572 0.86 PTGS2 (1.00) PTGS2AKR1C3LMNAAKR1C2MEN1
Mefenamic Acid SCHEMBL29465887 0.86 PTGS2 (1.00) PTGS2AKR1C3LMNAAKR1C2MEN1
SCHEMBL25449209 0.85 AKR1C3 (0.66) PTGS2AKR1C3LMNAAKR1C2MEN1
SCHEMBL11013710 0.85 PTGS2 (0.73) PTGS2AKR1C3LMNAAKR1C2MEN1
Mefenamic Acid SCHEMBL16179956 0.85 PTGS2 (0.97) PTGS2AKR1C3LMNAAKR1C2MEN1
Mefenamic Acid SCHEMBL678182 0.85 PTGS2 (0.97) PTGS2AKR1C3LMNAAKR1C2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4272761-A2 COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS Medicon Pharmaceuticals, Inc. (US) 2023-11-08 EP disclosed
US-20230293557-A1 COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS MEDICON PHARMACEUTICALS INC (US) 2023-09-21 US disclosed
US-20230293557-A1 COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS MEDICON PHARMACEUTICALS INC (US) 2023-09-21 US disclosed
US-20230219886-A1 NOVEL SELENO-NSAID ANALOGS AND USES THEREOF THE PENN STATE RESEARCH FOUNDATION 2023-07-13 US disclosed
WO-2018115984-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION CELLIX BIO PRIVATE LIMITED (IN) 2018-06-28 WO disclosed
WO-2018064354-A1 COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS MEDICON PHARMACEUTICALS, INC. (US) 2018-04-05 WO disclosed
US-20150306232-A1 HYDROGELATORS COMPRISING D-AMINO ACIDS BRANDEIS UNIVERSITY 2015-10-29 US disclosed
US-20150148306-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION KANDULA MAHESH (IN) 2015-05-28 US disclosed
WO-2014091467-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATION KANDULA MAHESH (IN) 2014-06-19 WO disclosed
WO-2014083476-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIPID DISORDERS KANDULA MAHESH (IN) 2014-06-05 WO disclosed
US-8569335-B2 Compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these EMS S.A. (BR) 2013-10-29 US disclosed
US-20110118303-A1 NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE EMS S.A. (BR) 2011-05-19 US disclosed
US-20110118303-A1 NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE EMS S.A. (BR) 2011-05-19 US disclosed
WO-2009124371-A9 NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE EMS S. A. (BR) 2010-12-02 WO disclosed
US-20100298360-A1 SMALL MOLECULE INHIBITORS OF PDZ INTERACTIONS BELMARES MICHAEL P 2010-11-25 US disclosed
WO-2010078486-A2 OPIOID-CONTAINING ORAL PHARMACEUTICAL COMPOSITIONS AND METHODS UPSHER-SMITH LABORATORIES, INC. (US) 2010-07-08 WO disclosed
WO-2009124371-A2 NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE EMS S. A. (BR) 2009-10-15 WO disclosed
US-20090062213-A1 Small Molecule Inhibitors of PDZ Interactions ARBOR VITA CORPORATION (US) 2009-03-05 US disclosed
US-7432261-B2 Anti-inflammatory phosphonate compounds GILEAD SCIENCES, INC. (US) 2008-10-07 US disclosed
US-20080227684-A1 Small Molecule Inhibitors of PDZ Interactions NONO INC. (CA) 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062213-A1 Small Molecule Inhibitors of PDZ Interactions PDLIM5, DAB2IP, PSD PTGS2 4529/4885AKR1C3 4659/4885LMNA 4338/4885
US-20150148306-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION IAPP, TTR, GPR119 PTGS2 2226/4885AKR1C3 400/4885LMNA 2155/4885
US-20230293557-A1 COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS PDE6C, PDE6H, PDE6D PTGS2 101/4885AKR1C3 191/4885LMNA 816/4885
US-20150306232-A1 HYDROGELATORS COMPRISING D-AMINO ACIDS DNPEP, S100A10, S100A11 PTGS2 622/4885AKR1C3 4569/4885LMNA 4707/4885
US-20080227684-A1 Small Molecule Inhibitors of PDZ Interactions PDLIM5, DAB2IP, PSD PTGS2 4529/4885AKR1C3 4659/4885LMNA 4338/4885
US-20100298360-A1 SMALL MOLECULE INHIBITORS OF PDZ INTERACTIONS PDLIM5, DAB2IP, PSD PTGS2 4529/4885AKR1C3 4659/4885LMNA 4338/4885
US-20110118303-A1 NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE TPMT, UTS2R, NSUN3 PTGS2 217/4885AKR1C3 594/4885LMNA 3909/4885
US-20230219886-A1 NOVEL SELENO-NSAID ANALOGS AND USES THEREOF SELENOI, SCLY, GPX1 PTGS2 14/4885AKR1C3 1586/4885LMNA 4147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.